The ASSURE Study: HIV-1 Suppression Is Maintained with Bone and Renal Biomarker Improvement 48 Weeks after Ritonavir Discontinuation and Randomized Switch to Abacavir/Lamivudine + Atazanavir. HIV Medicine, 17(2): 106-117.

In by AHF